Skip to main content

Table 3 BiTes currently in FL trials

From: Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies

BiTe NCT#/publication Route/Administration schedule Phase Total n [FL] Median lines of prior therapy % POD24 ORR%a [CR%] mPFS CRS % [G ≥ 3] Neuro % [G ≥ 3] Approved
Mosunetuzumab [96] IV Qweekly for cycle 1, Q21 days for cycles ≥ 2, stopped after cycle 8 for CR 1 62 [62] 3 48 68 [50] 11.8 2 0
Odronextumab [97] IV Qweekly for weeks 1–12, Q2 weeks for weeks 12–36 1 96 [25] 3 NP 93 [71] NP 7 3
Odronextumab NCT03888105 [98] IV Qweekly for weeks 1–12, Q2 weeks for weeks 12–36 II NAb NAb NAb NAb NAb NAb NAb
Epcoritamab [100] sq Qweekly C1-2, Q2 weeks C3-6, Q4 weeks thereafter, 28 day cycles I 67 [12] 3 NP 100 [25] NP 0 3
Glofitamab [108] Obinutuzumab on D-7, weekly for two weeks then Q2 weeks for 28 weeks I 171 [44] 3 NP 62 [52]c 11.8 3.5 1.2
  1. Abbreviations: CRS—cytokine release syndrome; CR—complete response rate; Neuro—neurotoxicity; NP—not presented; ORR—overall response rate; PFS—progression-free survival; POD24—progression of disease within 24 months following chemoimmunotherapy; sq—subcutaneous; Qweekly—every week; Q2 weeks—every 2 weeks
  2. aResponse rates in FL subset
  3. bNot available, clinical trial is ongoing
  4. cfor cohorts receiving ≥ 10 mg dosing